Our Review Summarypublished in the Annals of Oncology. Echoing the optimistic framing of a news release, this Newsweek story focused on the fact that some patients who took their drug saw their tumors shrink, including a quote calling the findings “very encouraging.” It also overlooked discussion of potential harms and and didn’t caution readers that tumor shrinkage doesn’t necessarily lead to longer survival. Why This MattersNearly half of women in the U.S. diagnosed with ovarian cancer don’t live more than five years. Targeted therapies like this one — which are designed to attack specific vulnerabilities in cancer cells — are being tested to treat cases that recur or resist standard treatment with surgery or chemotherapy. While targeted therapies are an important area of research, the public shouldn’t be oversold on early-phase trials or led to think that tumor shrinkage portends a cure. Criteria Not Satisfactory There’s … [Read more...] about Newsweek’s premature optimism about experimental ovarian cancer drug overlooks costs, harms and limitations of the evidence
Experimental lung cancer treatments
Visit The Boston Globe Share on Twitter Share on Facebook Comment on this Scroll to top of page By Amy Sutherland May 16, 2018 DRAMBUIE THE GOLDEN RETRIEVER lies on his back on the floor, paws in the air, as his owner runs her hands over him. On this December night, like every night, Gina Alongi searches for sore spots and ticks, her fingers feeling for anything that might be amiss with her beloved dog. She starts with his chest and traces circles with her index and middle fingers down his torso. When she reaches the bare skin of his abdomen she pauses. She feels a small lump.It’s been eight years since Alongi flew to Ohio to buy a horse, only to come home with a new dog. Amid the thousands of quarter horses at this annual sale, one tent sold puppies. By the end of the day, there was a single one left. He looked so sad by himself. Alongi snuck him into her hotel room and then bought an additional plane ticket to fly him back to Westborough with her. Drambuie … [Read more...] about An experimental cancer treatment cured this dog. Could it work for people?
Some cancer centers are misleading the public by advertising clinical trials as a way for patients to access cutting-edge treatments, two ethics professors argue in a paper published today. Billboards like this one imply that clinical trials amount to a patient benefit, two ethicists say. Alex John London, PhD, of Carnegie Mellon University and Jonathan Kimmelman, PhD, of McGill University wrote in JAMA Oncology that “strong messages equating access to clinical trials with therapy imply that unproven drugs are already established as therapy.” They said those messages contradict the very purpose of a clinical trial, which is to determine whether a therapy works. Among the examples they cited: A billboard erected by the Georgia Cancer Center declares: “Clinical Trials: Another Reason to See Us First.” In a Johns Hopkins Medicine video, a doctor says clinical trials “open up new treatments that (his patients) otherwise would not have available to … [Read more...] about Ethicists find fault with cancer centers marketing their clinical trials as a patient benefit
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023. This is the second deal AbbVie has signed over the past year as it tries to safeguard patents on Humira, which is the world’s top-selling prescription medicine. The drug, which treats rheumatoid arthritis, raked in $18.43 billion in sales last year and accounted for nearly two-thirds of AbbVie’s net revenue. While terms of the deal were undisclosed, AbbVie said it will make no payments to Samsung Bioepis and the three companies agreed to dismiss all pending lawsuits. Even if multiple Humira biosimilars are delayed from market until 2023, this can be “more than offset” by a steeper sales decline for Humira, BMO Capital Markets analyst Alex Arfaei said. Arfaei noted this is increasingly likely given the U.S. Food and Drug … [Read more...] about AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in…
Researchers are now developing a new method of killing cancer more effectively. Their strategy "starves" tumors, depriving them of the main nutrient they require to grow and spread. Glutamine is an amino acid that is abundantly found in our bodies, especially in blood and bone tissue. Its main role is to sustain the synthesis of proteins in cells. Unfortunately, though, glutamine is also a key nutrient for many types of cancerous tumors, which tend to "consume" more of this amino acid because their cells divide more rapidly. This is why research has been investigating the possibility of blocking cancer cells' access to glutamine as a new therapeutic approach in cancer treatment. Charles Manning and several other researchers from the Vanderbilt Center for Molecular Probes at Vanderbilt University in Nashville, TN, have now managed, in a breakthrough move, to stop the growth of a cancer tumor. To do so, they used an experimental compound called V-9302 to block the uptake, or absorption, … [Read more...] about Cancer breakthrough: Novel approach can ‘starve’ tumors to death